|
JP5977837B2
(ja)
|
2011-12-21 |
2016-08-24 |
ノヴィラ・セラピューティクス・インコーポレイテッド |
Ｂ型肝炎抗ウイルス剤
|
|
KR102115047B1
(ko)
|
2012-04-03 |
2020-05-26 |
노파르티스 아게 |
티로신 키나제 억제제들을 갖는 조합 제품 및 그의 용도
|
|
MX373711B
(es)
|
2012-08-28 |
2020-05-08 |
Janssen Sciences Ireland Uc |
Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b.
|
|
US9573958B2
(en)
|
2012-08-31 |
2017-02-21 |
Principia Biopharma, Inc. |
Benzimidazole derivatives as ITK inhibitors
|
|
DK2961732T3
(en)
|
2013-02-28 |
2017-07-10 |
Janssen Sciences Ireland Uc |
SULFAMOYLARYLAMIDS AND USE THEREOF AS MEDICINES TO TREAT HEPATITIS B
|
|
UY35464A
(es)
|
2013-03-15 |
2014-10-31 |
Araxes Pharma Llc |
Inhibidores covalentes de kras g12c.
|
|
CN105102451B
(zh)
|
2013-04-03 |
2018-09-18 |
爱尔兰詹森科学公司 |
N-苯基-氨甲酰衍生物及其作为药物用于治疗乙型肝炎的用途
|
|
DK2997019T3
(en)
|
2013-05-17 |
2018-12-03 |
Janssen Sciences Ireland Uc |
SULFAMOYLTHIOPHENAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B
|
|
JO3603B1
(ar)
|
2013-05-17 |
2020-07-05 |
Janssen Sciences Ireland Uc |
مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
|
|
KR102244937B1
(ko)
|
2013-07-25 |
2021-04-27 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
글리옥사미드 치환된 피롤아미드 유도체 및 ｂ형 간염 치료용 의약으로서의 이의 용도
|
|
WO2015048312A1
(en)
|
2013-09-26 |
2015-04-02 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Ｋｒａｓ ｇ１２ｃ之抑制劑
|
|
DK3060547T3
(en)
|
2013-10-23 |
2018-01-15 |
Janssen Sciences Ireland Uc |
CARBOXAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATMENT OF HEPATITS B
|
|
WO2015085482A1
(en)
*
|
2013-12-10 |
2015-06-18 |
Novartis Ag |
Egfr inhibitor forms
|
|
WO2015083059A1
(en)
*
|
2013-12-02 |
2015-06-11 |
Novartis Ag |
Forms of the egfr inhibitor
|
|
WO2015081463A1
(en)
*
|
2013-12-02 |
2015-06-11 |
Novartis Ag |
Egfr inhibitor forms
|
|
US9169212B2
(en)
|
2014-01-16 |
2015-10-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
US10392349B2
(en)
|
2014-01-16 |
2019-08-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
EP3102225B1
(en)
|
2014-02-05 |
2020-03-25 |
Novira Therapeutics Inc. |
Combination therapy for treatment of hbv infections
|
|
US11078193B2
(en)
|
2014-02-06 |
2021-08-03 |
Janssen Sciences Ireland Uc |
Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
|
|
WO2015134210A1
(en)
*
|
2014-03-03 |
2015-09-11 |
Principia Biopharma, Inc. |
BENZIMIDAZOLE DERIVATIVES AS RLK and ITK INHIBITORS
|
|
KR20240110004A
(ko)
|
2014-03-14 |
2024-07-12 |
노파르티스 아게 |
Lag-3에 대한 항체 분자 및 그의 용도
|
|
US10202398B2
(en)
|
2014-03-20 |
2019-02-12 |
Capella Therapeutics, Inc. |
Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
|
|
CN114940673B
(zh)
|
2014-03-20 |
2025-03-18 |
卡佩拉医疗公司 |
苯并咪唑衍生物作为erbb酪氨酸激酶抑制剂用于治疗癌症
|
|
WO2015145388A2
(en)
|
2014-03-27 |
2015-10-01 |
Novartis Ag |
Methods of treating colorectal cancers harboring upstream wnt pathway mutations
|
|
WO2016016822A1
(en)
|
2014-07-31 |
2016-02-04 |
Novartis Ag |
Combination therapy
|
|
ES2771926T3
(es)
*
|
2014-09-13 |
2020-07-07 |
Novartis Ag |
Terapias de combinación
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
JP2017535528A
(ja)
|
2014-10-03 |
2017-11-30 |
ノバルティス アーゲー |
組み合わせ治療
|
|
WO2016055916A1
(en)
|
2014-10-06 |
2016-04-14 |
Novartis Ag |
Therapeutic combination for the treatment of cancer
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
US9988452B2
(en)
|
2014-10-14 |
2018-06-05 |
Novartis Ag |
Antibody molecules to PD-L1 and uses thereof
|
|
JP6692826B2
(ja)
|
2015-03-10 |
2020-05-13 |
アドゥロ バイオテック，インク． |
「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法
|
|
US9884831B2
(en)
|
2015-03-19 |
2018-02-06 |
Novira Therapeutics, Inc. |
Azocane and azonane derivatives and methods of treating hepatitis B infections
|
|
EP3280708B1
(en)
|
2015-04-10 |
2021-09-01 |
Araxes Pharma LLC |
Substituted quinazoline compounds and methods of use thereof
|
|
JP6789239B2
(ja)
|
2015-04-15 |
2020-11-25 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法
|
|
EP3294299A1
(en)
*
|
2015-05-15 |
2018-03-21 |
Novartis AG |
Methods for treating egfr mutant cancers
|
|
US20180153899A1
(en)
*
|
2015-05-22 |
2018-06-07 |
Novartis Ag |
Pharmaceutical compositions
|
|
WO2017004383A1
(en)
|
2015-06-30 |
2017-01-05 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of egfr and methods of use thereof
|
|
US10875876B2
(en)
|
2015-07-02 |
2020-12-29 |
Janssen Sciences Ireland Uc |
Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
EP3328407A1
(en)
*
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination of pd-1 antagonist with an egfr inhibitor
|
|
CN108025051B
(zh)
|
2015-07-29 |
2021-12-24 |
诺华股份有限公司 |
包含抗pd-1抗体分子的联合疗法
|
|
WO2017019894A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to lag-3
|
|
CN108602776B
(zh)
*
|
2015-09-18 |
2021-12-03 |
默克专利有限公司 |
用作irak抑制剂的杂芳基化合物及其用途
|
|
US10590108B2
(en)
|
2015-09-23 |
2020-03-17 |
Capella Therapeutics, Inc. |
Benzimidazoles for use in the treatment of cancer and inflammatory diseases
|
|
EP3356347A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356354A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058768A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058792A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058915A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356339A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
TW201718496A
(zh)
|
2015-09-29 |
2017-06-01 |
諾維拉治療公司 |
B型肝炎抗病毒劑之晶型
|
|
HRP20220436T1
(hr)
|
2015-11-03 |
2022-05-27 |
Janssen Biotech, Inc. |
Protutijela koja se specifično vežu na pd-1 i njihove uporabe
|
|
EA038635B9
(ru)
|
2015-11-16 |
2021-10-26 |
Араксис Фарма Ллк |
2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
|
|
CA3007671A1
(en)
|
2015-12-17 |
2017-06-22 |
Novartis Ag |
Antibody molecules to pd-1 and uses thereof
|
|
RU2018137389A
(ru)
*
|
2016-04-07 |
2020-05-12 |
Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Гетероциклические амиды, полезные в качестве модуляторов
|
|
WO2017175144A1
(en)
|
2016-04-08 |
2017-10-12 |
Novartis Ag |
New therapeutic uses
|
|
CN109640980A
(zh)
|
2016-04-15 |
2019-04-16 |
诺维拉治疗公司 |
包含壳体装配抑制剂的组合和方法
|
|
US20170321285A1
(en)
*
|
2016-05-03 |
2017-11-09 |
The Texas A&M University System |
Nlrc5 as a biomarker for cancer patients and a target for cancer therapy
|
|
US11098077B2
(en)
|
2016-07-05 |
2021-08-24 |
Chinook Therapeutics, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
CN107663170B
(zh)
*
|
2016-07-29 |
2020-02-11 |
广东东阳光药业有限公司 |
制备贝西沙星中间体化合物的方法
|
|
CA2939286A1
(en)
*
|
2016-08-17 |
2018-02-17 |
Pharmascience Inc. |
Spirocyclic containing compounds and pharmaceutical uses thereof
|
|
EP3519402A1
(en)
|
2016-09-29 |
2019-08-07 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
US10377743B2
(en)
|
2016-10-07 |
2019-08-13 |
Araxes Pharma Llc |
Inhibitors of RAS and methods of use thereof
|
|
WO2018112090A1
(en)
*
|
2016-12-13 |
2018-06-21 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Methods of treating cancers containing fusion genes
|
|
EP3573967A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused hetero-hetero bicyclic compounds and methods of use thereof
|
|
WO2018140512A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
US11358959B2
(en)
|
2017-01-26 |
2022-06-14 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
US11279689B2
(en)
|
2017-01-26 |
2022-03-22 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
|
|
WO2018140514A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
|
|
CN106946779A
(zh)
*
|
2017-02-13 |
2017-07-14 |
广州仁恒医药科技股份有限公司 |
一种r‑3‑氨基‑六氢氮杂*的制备方法
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
JP2020521741A
(ja)
|
2017-05-25 |
2020-07-27 |
アラクセス ファーマ エルエルシー |
がんの処置のための化合物およびその使用の方法
|
|
CA3063440A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Covalent inhibitors of kras
|
|
CN110831933A
(zh)
|
2017-05-25 |
2020-02-21 |
亚瑞克西斯制药公司 |
喹唑啉衍生物作为突变kras、hras或nras的调节剂
|
|
EP3641812A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
|
WO2018235056A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Il-1beta binding antibodies for use in treating cancer
|
|
CA3061874A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Il-1beta binding antibodies for use in treating cancer
|
|
WO2018237173A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
WO2019026006A1
(en)
|
2017-08-03 |
2019-02-07 |
Novartis Ag |
THERAPEUTIC ASSOCIATION OF THIRD GENERATION EGFR TYROSINE KINASE INHIBITOR AND CYCLIN D KINASE INHIBITOR
|
|
MX2020001254A
(es)
|
2017-08-03 |
2020-03-20 |
Novartis Ag |
Combinacion terapeutica de un inhibidor tirosina quinasa del egfr de tercera generacion y un inhibidor raf.
|
|
CN109721605B
(zh)
*
|
2017-10-31 |
2022-03-11 |
维眸生物科技（上海）有限公司 |
一种免疫细胞迁徙抑制剂
|
|
KR20200096253A
(ko)
|
2017-11-30 |
2020-08-11 |
노파르티스 아게 |
Bcma-표적화 키메라 항원 수용체, 및 이의 용도
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
US11174245B2
(en)
|
2018-02-21 |
2021-11-16 |
Boehringer Ingelheim International Gmbh |
Benzimidazole compounds and derivatives as EGFR inhibitors
|
|
JP2021515769A
(ja)
|
2018-03-14 |
2021-06-24 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
カプシド集合調節剤の投薬レジメン
|
|
CA3094948A1
(en)
|
2018-04-18 |
2019-10-24 |
Novartis Ag |
Nazartinib for use in the treatment of cns metastasis
|
|
PT3784664T
(pt)
|
2018-04-26 |
2025-04-23 |
Pfizer |
Derivados da 2-amino-piridina ou da 2-amino-pirimidina como inibidores da quinase dependente da ciclina
|
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
UY38251A
(es)
|
2018-06-01 |
2019-12-31 |
Novartis Ag |
Moléculas de unión contra bcma y usos de las mismas
|
|
EP3829580A1
(en)
|
2018-08-01 |
2021-06-09 |
Araxes Pharma LLC |
Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
|
|
WO2020128613A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1beta binding antibodies
|
|
CN109369620B
(zh)
*
|
2018-12-22 |
2020-04-14 |
山东大学 |
吡啶类化合物及其制备方法与抗胃癌应用
|
|
MA55020A
(fr)
|
2019-02-22 |
2021-12-29 |
Janssen Sciences Ireland Unlimited Co |
Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
|
|
CN111747931A
(zh)
|
2019-03-29 |
2020-10-09 |
深圳福沃药业有限公司 |
用于治疗癌症的氮杂芳环酰胺衍生物
|
|
AR119732A1
(es)
|
2019-05-06 |
2022-01-05 |
Janssen Sciences Ireland Unlimited Co |
Derivados de amida útiles en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb
|
|
WO2020260252A1
(en)
|
2019-06-24 |
2020-12-30 |
Boehringer Ingelheim International Gmbh |
New macrocyclic compounds and derivatives as egfr inhibitors
|
|
EP4031578A1
(en)
|
2019-09-18 |
2022-07-27 |
Novartis AG |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
CN114502555B
(zh)
*
|
2019-10-15 |
2024-07-16 |
常州千红生化制药股份有限公司 |
用于治疗增殖性疾病和疾患的4-(咪唑并[1,2-a]吡啶-3-基)-N-(吡啶-3-基)嘧啶-2-胺的衍生物
|
|
KR102267662B1
(ko)
*
|
2019-11-19 |
2021-06-22 |
한국화학연구원 |
벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
|
|
EP4146217A1
(en)
|
2020-05-08 |
2023-03-15 |
Novartis AG |
Pharmaceutical combination comprising tno155 and nazartinib
|
|
JP2023526443A
(ja)
*
|
2020-05-18 |
2023-06-21 |
ウェルマーカー バイオ カンパニー リミテッド |
Ｒｏｎ変異が関与する非小細胞肺がんの予防又は治療用医薬組成物及びその使用方法
|
|
KR20210142553A
(ko)
*
|
2020-05-18 |
2021-11-25 |
웰마커바이오 주식회사 |
Ron 돌연변이와 관련된 소세포 폐암 예방 또는 치료용 약학 조성물 및 이를 이용한 방법
|
|
EP4154890A4
(en)
*
|
2020-05-18 |
2023-12-06 |
Wellmarker Bio Co., Ltd. |
PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF PANCREATIC CANCER ASSOCIATED WITH RON MUTATION AND METHOD USING SAME
|
|
US20210369709A1
(en)
|
2020-05-27 |
2021-12-02 |
Astrazeneca Ab |
EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
|
|
CN113880804A
(zh)
*
|
2020-07-01 |
2022-01-04 |
微境生物医药科技(上海)有限公司 |
新型苯并咪唑化合物
|
|
CA3195035A1
(en)
*
|
2020-10-12 |
2022-04-21 |
Dana Farber Cancer Institute, Inc. |
Covalent egfr inhibitors and methods of use thereof
|
|
US12064421B2
(en)
|
2020-11-02 |
2024-08-20 |
Boehringer Ingelheim International Gmbh |
Substituted 1H-pyrazolo[4,3-c]pyridines and derivatives as EGFR inhibitors
|
|
IL302569A
(en)
|
2020-11-06 |
2023-07-01 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
CN117396463A
(zh)
*
|
2021-05-17 |
2024-01-12 |
怡诺安有限公司 |
用于预防或治疗癌症的苯甲酰胺衍生物、其制备方法和含有其作为活性成分的药物组合物
|
|
CN115368378B
(zh)
*
|
2021-05-21 |
2024-11-19 |
深圳市塔吉瑞生物医药有限公司 |
取代的大环化合物及包含该化合物的组合物及其用途
|
|
WO2022265950A1
(en)
|
2021-06-15 |
2022-12-22 |
Genentech, Inc. |
Egfr inhibitor and perk activator in combination therapy and their use for treating cancer
|
|
WO2023069959A1
(en)
*
|
2021-10-18 |
2023-04-27 |
Dana-Farber Cancer Institute, Inc. |
Covalent egfr inhibitors and methods of use thereof
|
|
KR102572664B1
(ko)
*
|
2022-02-07 |
2023-08-30 |
주식회사 인터엠 |
오디오 클록 조정 및 이를 이용한 네트워크 기반 전관 방송
|
|
WO2023209088A1
(en)
|
2022-04-28 |
2023-11-02 |
Astrazeneca Ab |
Bicyclic heteroaromatic compounds and their use in the treatment of cancer
|
|
WO2023209090A1
(en)
|
2022-04-28 |
2023-11-02 |
Astrazeneca Ab |
Bicyclic heteroaromatic compounds and their application in the treatment of cancer
|
|
WO2023209086A1
(en)
|
2022-04-28 |
2023-11-02 |
Astrazeneca Ab |
Bicyclic heteroaromatic compounds for treating cancer
|
|
WO2023209084A1
(en)
|
2022-04-28 |
2023-11-02 |
Astrazeneca Ab |
Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
|
|
AU2023294689A1
(en)
*
|
2022-06-14 |
2025-01-30 |
Principia Biopharma Inc. |
Methods of making tolebrutinib
|
|
TW202416963A
(zh)
*
|
2022-09-02 |
2024-05-01 |
大陸商迪哲（江蘇）醫藥股份有限公司 |
Ｅｇｆｒ抑制劑及其用途
|